The mode of action of the aminosalicylates in inflammatory bowel disease
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
SUMMARY: Sulphasalazine and other 5‐aminosalicylic acid (5‐ASA)‐containing drugs are used in the treatment of acute inflammatory bowel disease and in the maintenance of clinical remission. Despite their use for over 50 years, the mechanism of action of this class of drugs remains uncertain, although a number of possibilities are discussed in this review. It seems likely that the aminosalicylates are important free radical scavengers, can reduce leukotriene production and can inhibit the cellular release of interleukin‐1, all of which are likely to be important in reducing the acute inflammatory response in inflammatory bowel disease, The effects of these drugs on prostaglandin production are more contentious, but it appears that 10‐5 to 10‐4 M concentrations stimulate production of prostaglandins which may be cytoprotective, while higher doses of these drugs inhibit prostaglandin production. The aminosalicylates may maintain remission in inflammatory bowel disease by preventing leucocyte recruitment into the bowel wall. The drugs inhibit the chemotactic response to leukotriene B 4, reduce the synthesis of platelet activating factor and also inhibit leucocyte adhesion molecule upregulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease
Sharon, P., & Stenson, W. F. (1984) · Gastroenterology · doi:10.1016/s0016-5085(84)80015-3 · Cited by 738
THE ROLE OF INTESTINAL BACTERIA IN THE METABOLISM OF SALICYLAZOSULFAPYRIDINE
PEPPERCORN, M. A., & GOLDMAN, P. (1972) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29238-2 · Cited by 450
Chemotactic activity in inflammatory bowel disease: Role of leukotriene B4
Lobos, E. A., Sharon, P., & Stenson, W. F. (1987) · Digestive Diseases and Sciences · doi:10.1007/bf01296664 · Cited by 143
Cited by
Review of the biology of quercetin and related bioflavonoids
Formica, J. V., & Regelson, W. (1995) · Food and Chemical Toxicology · doi:10.1016/0278-6915(95)00077-1 · Cited by 1,765
Colonocyte metabolism shapes the gut microbiota
Litvak, Y., Byndloss, M. X., & Bäumler, A. J. (2018) · Science · doi:10.1126/science.aat9076 · Cited by 764
NUGENT, S. G., KUMAR, D., RAMPTON, D. S., & EVANS, D. F. (2001) · Gut · doi:10.1136/gut.48.4.571 · Cited by 700
Rousseaux, C., Lefebvre, B., Dubuquoy, L., Lefebvre, P., Romano, O., Auwerx, J., Metzger, D., Wahli, W., Desvergne, B., Naccari, G. C., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041948 · Cited by 526
Sood, A., Midha, V., Makharia, G. K., Ahuja, V., Singal, D., Goswami, P., & Tandon, R. K. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.07.016 · Cited by 513
Metadata
- Authors
- GREENFIELD, S. M., PUNCHARD, N. A., TEARE, J. P., & THOMPSON, R. P. H.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 1993-08
- Volume
- 7
- Issue
- 4
- Pages
- 369-383
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2053331429
- Cited by
- 144
- References
- 3
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The mode of action of the aminosalicylates in inflammatory bowel disease. https://app.cochat.ai/papers/10.1111/j.1365-2036.1993.tb00110.x
- The paper
- GREENFIELD, S. M., PUNCHARD, N. A., TEARE, J. P., & THOMPSON, R. P. H. (1993). The mode of action of the aminosalicylates in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.1993.tb00110.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.